Vaxcyte Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Grant Pickering

Amministratore delegato

US$12.1m

Compenso totale

Percentuale dello stipendio del CEO	5.3%
Mandato del CEO	11yrs
Proprietà del CEO	0.5%
Durata media del management	4.5yrs
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Grant Pickering rispetto agli utili di Vaxcyte?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$508m
Jun 30 2024	n/a	n/a	-US$497m
Mar 31 2024	n/a	n/a	-US$437m
Dec 31 2023	US$12m	US$640k	-US$402m
Sep 30 2023	n/a	n/a	-US$300m
Jun 30 2023	n/a	n/a	-US$265m
Mar 31 2023	n/a	n/a	-US$245m
Dec 31 2022	US$14m	US$601k	-US$223m
Sep 30 2022	n/a	n/a	-US$174m
Jun 30 2022	n/a	n/a	-US$143m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$5m	US$575k	-US$100m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$87m
Mar 31 2021	n/a	n/a	-US$83m
Dec 31 2020	US$3m	US$481k	-US$89m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$73m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$596k	US$426k	-US$50m

Compensazione vs Mercato: La retribuzione totale di Grant ($USD 12.14M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.81M ).

Compensazione vs guadagni: La retribuzione di Grant è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Grant Pickering (56 yo)

11yrs

Mandato

US$12,135,683

Compensazione

Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Grant Pickering	Co-Founder	11yrs	US$12.14m	0.53% € 56.1m
Andrew Guggenhime	President & CFO	4.5yrs	US$5.42m	0.059% € 6.3m
James Wassil	Executive VP & COO	4.9yrs	US$5.40m	0.14% € 14.7m
Mikhail Eydelman	Senior VP	2.6yrs	US$3.49m	0.0081% € 858.9k
Ashish Khanna	Co-Founder	11.8yrs	Nessun dato	Nessun dato
Jeff Fairman	Co-Founder & VP of Research	no data	Nessun dato	Nessun dato
Elvia Cowan	Senior VP of Finance & Principal Accounting Officer	1.8yrs	Nessun dato	0.0031% € 331.1k
Janet Graesser	Senior Vice President of Corporate Communications & Investor Relations	no data	Nessun dato	Nessun dato
Whitney Jones	Chief People Officer	less than a year	Nessun dato	Nessun dato
Paul Sauer	Senior Vice President of Process Development & Manufacturing	8.6yrs	US$2.35m	Nessun dato
Harp Dhaliwal	Senior Vice President of Commercial Manufacturing & Supply Chain	3yrs	US$1.84m	Nessun dato
Sam Iki	Senior Vice President of Project Management	no data	Nessun dato	Nessun dato

4.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 5VA è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Grant Pickering	Co-Founder	11yrs	US$12.14m	0.53% € 56.1m
Annie Drapeau	Independent Director	3.2yrs	US$704.22k	0.0045% € 477.1k
K. Hirth	Independent Director	8.2yrs	US$696.72k	0.010% € 1.1m
Heath Lukatch	Independent Director	6.5yrs	US$691.72k	0.0045% € 477.1k
Halley Gilbert	Independent Director	4.6yrs	US$704.22k	0.0045% € 477.1k
Emmanuel Walter	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Carlos Paya	Independent Chairman of the Board	3.1yrs	US$724.22k	0.0045% € 477.1k
Anthony Ford-Hutchinson	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jeffrey Almond	Member of Scientific Advisory Board	7.8yrs	Nessun dato	Nessun dato
Teri Loxam	Independent Director	3.2yrs	US$704.22k	0.0045% € 477.1k
Emmanuel Hanon	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
William Hausdorff	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

5.5yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 5VA sono considerati esperti (durata media dell'incarico 5.5 anni).

Vaxcyte Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

Recent updates

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

New major risk - Shareholder dilution

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media